Looks like they've dragged $2.74m from operating expenses (staff costs and operating costs) and capitalised in R&D. Not much changed on that front. All well and good to get closer to cashflow breakeven, but at $22m market cap need to confirm revenue growth trajectory, particularly ARR, and 13% yoy not really cutting it.
